NCT05583188 2024-07-19
VIGOR
Galvanize Therapeutics, Inc.
Phase 4 Terminated
Clinical Trials
5 trialsNCT02869789 2023-06-15
An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
Bristol-Myers Squibb
Phase 4 Completed
NCT03313544 2023-04-21
Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1
Assistance Publique Hopitaux De Marseille
Phase 4 Unknown
NCT03444766 2020-12-04
Study of Nivolumab for Advanced Cancers in India
Bristol-Myers Squibb
Phase 4 Completed
NCT04331626 2020-04-02
Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC
Henan Cancer Hospital
Phase 4 Unknown